2024-03-28T18:28:55Zhttps://uvadoc.uva.es/oai/requestoai:uvadoc.uva.es:10324/90542021-06-23T09:49:05Zcom_10324_1133com_10324_931com_10324_894col_10324_1209
Carvajal García-Pando, Alfonso
Macías, Diego
Salado Valdivieso, María Inés
Sáinz Gil, María
Ortega, Sara
Campo, C.
García del Pozo, Javier
Martín Arias, Luis Hermenegildo
Velasco Martín, Alfonso
Gonçalves, R.
Pombal, R.
Carmona, R.
2015-03-09T12:41:09Z
2015-03-09T12:41:09Z
2009
Clinical Pharmacology and Therapeutics. 2009 May;85(5):481-4
0009-9236
http://uvadoc.uva.es/handle/10324/9054
10.1038/clpt.2008.269
481
5
484
Clinical Pharmacology and Therapeutics
85
Producción Científica
We searched the Spanish and Portuguese pharmacovigilance databases for spontaneous case reports of heart rhythm disturbances associated with rupatadine and other new H1 antihistamines. Five cases were found involving patients treated with rupatadine (13.9% of all reports relating to this drug). In all five cases, the reaction started after exposure and resolved when the drug was discontinued. In two cases, rupatadine was the only medication being taken by the patient, and no other condition that could explain the heart rhythm disturbances was diagnosed. The reporting odds ratio was 3.2 (95% confidence interval, 1.0-10.5). The reporting rate was 2 cases per 100,000 patients treated per year (95% confidence interval, 0.4-6.0). These results suggest a causal relationship between rupatadine and heart rhythm disturbances
Junta de Castilla y León. Consejería de Sanidad. Dirección General de Salud Pública e Investigación, Desarrollo e Innovación.
application/pdf
eng
American Society for Clinical Pharmacology and Therapeutics
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-nd/4.0/
Attribution-NonCommercial-NoDerivatives 4.0 International
Insuficiencia cardiaca
Rupatadina
Heart rhythm risturbances associated with rupatadine: a case series from the Spanish and Portuguese Pharmacovigilance Systems
info:eu-repo/semantics/article
SI